Relay-Version: version B 2.10 5/3/83; site utzoo.UUCP
Posting-Version: version B 2.10.2 9/5/84; site aecom.UUCP
Path: utzoo!watmath!clyde!burl!ulysses!allegra!mit-eddie!think!harvard!cmcl2!philabs!aecom!werner
From: werner@aecom.UUCP (Craig Werner)
Newsgroups: net.med
Subject: Treatment for diabetes-related eye trouble
Message-ID: <1927@aecom.UUCP>
Date: Tue, 1-Oct-85 11:29:08 EDT
Article-I.D.: aecom.1927
Posted: Tue Oct  1 11:29:08 1985
Date-Received: Thu, 3-Oct-85 06:56:30 EDT
Distribution: na
Organization: Albert Einstein Coll. of Med., NY
Lines: 20

From: AMN 9/13/85 p. 36
"Diabetics vision problem's aided."

	Suldinac, a non-steroidal anti-inflammatory drug (Aspirin,
Tylenol, and Motrin are also NSAIDs) appears to prevent blood-vessel
alterations associated with vision loss in diabetic patients, according to
a report in Sept. Archives of Opthamology.
	J.G. Cunha-Vaz, MD/PhD, et al, of U.Illinois compared Suldinac
treatment with placebo in a group of 24 Insulin-dependent diabetic
patients and found that treated patients "had a significant beneficial
effect on the breakdown of the blood-retinal barrier."  They say that long
term studies are now in order "to determine if the progression and
development of diabetic retinopathy and final vision loss can be
prevented."

-- 

				Craig Werner
				!philabs!aecom!werner
               "Why is it that half the calories is twice the price?"